000102205 001__ 102205 000102205 005__ 20230519145500.0 000102205 0247_ $$2doi$$a10.1007/s12094-021-02573-1 000102205 0248_ $$2sideral$$a124289 000102205 037__ $$aART-2021-124289 000102205 041__ $$aeng 000102205 100__ $$aGómez-España, Mª A. 000102205 245__ $$aSEOM clinical guidelines for pancreatic and biliary tract cancer (2020) 000102205 260__ $$c2021 000102205 5060_ $$aAccess copy available to the general public$$fUnrestricted 000102205 5203_ $$aPancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery is the only potentially curative therapy in both cancers, but disease recurrence is frequent. In PC, adjuvant treatment with mFOLFIRINOX has improved overall survival (OS) and in BTC adjuvant treatment with capecitabine seems to improve OS and relapse-free survival. Concomitant radio-chemotherapy could also be considered following R1 surgery in both neoplasms. Neoadjuvant treatment represents the best option for achieving an R0 resection in borderline PC. Upfront systemic chemotherapy is the treatment of choice in unresectable locally advanced PC and BTC; then locoregional therapy could be considered after an initial period of at least 3-4 months of systemic chemotherapy. In metastatic PC, FOLFIRINOX or Gemcitabine plus nab-paclitaxel have improved OS compared with gemcitabine alone. In metastatic BTC, cisplatin plus gemcitabine constitute the standard treatment. Progress in the knowledge of molecular biology has enabled the identification of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of patients with PC and BTC. 000102205 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000102205 590__ $$a3.34$$b2021 000102205 592__ $$a0.764$$b2021 000102205 594__ $$a5.5$$b2021 000102205 591__ $$aONCOLOGY$$b165 / 245 = 0.673$$c2021$$dQ3$$eT3 000102205 593__ $$aOncology$$c2021$$dQ2 000102205 593__ $$aMedicine (miscellaneous)$$c2021$$dQ2 000102205 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000102205 700__ $$aMontes, A.F. 000102205 700__ $$aGarcía-Carbonero, R. 000102205 700__ $$aMercadé, T.M. 000102205 700__ $$aMaurel, J. 000102205 700__ $$aMartín, A.M. 000102205 700__ $$0(orcid)0000-0002-8026-7391$$aPazo-Cid, R.$$uUniversidad de Zaragoza 000102205 700__ $$aVera, R. 000102205 700__ $$aFeliu, J. 000102205 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000102205 773__ $$g23 (2021), 988–1000$$pClin. transl. oncol.$$tClinical and Translational Oncology$$x1699-048X 000102205 8564_ $$s940481$$uhttps://zaguan.unizar.es/record/102205/files/texto_completo.pdf$$yVersión publicada 000102205 8564_ $$s1930998$$uhttps://zaguan.unizar.es/record/102205/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000102205 909CO $$ooai:zaguan.unizar.es:102205$$particulos$$pdriver 000102205 951__ $$a2023-05-18-14:55:28 000102205 980__ $$aARTICLE